novo nordisk wegovy - Search News

Ozempic, Wegovy face US Medicare price negotiations

Hosted on MSN · 13h

Novo Suffers Wegovy Trial Setback as US Plans to Cut Price

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early dominance in the surging market for new weight-loss treatments.

The Washington Post on MSN · 9h

Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

YAHOO!Finance · 15h

Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks

GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad Smith break down the details on Morning Brief.

High-dose Wegovy leads to substantial weight loss in trial

High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.

BioSpace · 14h

Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP trial to evaluate the effect of increasing the maximum dose to 7.2 mg. The trial randomized 1,407 adults with obesity, but not diabetes, to receive either 7.2 mg or 2.4 mg of semaglutide or placebo.

Wall Street Journal · 16h

Wegovy at Higher Dose Achieves Greater Weight Loss in Trial

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.

13hon MSN

These Stocks Are Moving the Most Today: Apple, Qorvo, Novo Nordisk, SLB, J.B. Hunt, Rivian, Cloudflare, and More

Stocks rallied sharply Friday and the S&P 500 was on pace for its best week since early November.These stocks were making ...

15hon MSN

Novo’s Wegovy Trails Lilly’s Zepbound in Higher-Dose Study

Raising the dose of Novo Nordisk A/S’s obesity drug Wegovy helped patients shed more pounds in a trial while still falling ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results